Aquestive Therapeutics, Inc. (AQST)
AQSTNASDAQ-GMBiotechnology: Pharmaceutical Preparations
$3.50
-0.0800 (-2.23%) today
At the close, Nov 11, 4:00 PM ET. Pre-market $3.50 -2.23%
- Market cap
- $439.91m
- P/E
- –
- EPS, last 4 quarters
- $-0.6400
- Dividend yield
- –
- Day range
- –
- 52-week range
- $2.93 to $6.74
- Average volume
- –
- Previous close
- $3.58
Analysts
4 coveringBuy4 buy, 0 hold, 0 sell
Targets a year out average $9.20, +162.9% from here
Earnings
next estimate $-0.1100Next report
Dec 2025
-100.0%
Mar 2026
+50.0%
Jun 2026
-80.0%
Sep 2026
-30.0%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $13.02m | $14.45m | $13.82m | $7.56m |
| Gross profit | $7.18m | $10.98m | $9.80m | $3.95m |
| Operating income | -$28.84m | -$4.20m | -$8.22m | -$14.47m |
| Net income | -$31.86m | -$8.06m | -$22.86m | -$16.50m |
Last four quarters: revenue $48.84m, margin -162.3%, free cash flow -$40.70m
News
8 latest- Aquestive (AQST) Q3 2026 Earnings Call TranscriptThe Motley Fool · Nov 4, 2026
- What Aquestive Therapeutics (AQST) Said on Its Q3 Earnings CallMarketBeat · Nov 4, 2026
- Aquestive Therapeutics Reports Third Quarter 2026 Financial Results and Provides Anaphylm UpdateFintel · Nov 3, 2026
- Aquestive Therapeutics (AQST) Reports Q3 Loss, Misses Revenue EstimatesZacks · Nov 3, 2026
- Aquestive Therapeutics Wins FDA Acceptance Of Anaphylm NDA Resubmission RTTNews · Oct 15, 2026
- Aquestive Says FDA Accepts Anaphylm NDA Resubmission For The Treatment Of Type I Allergic Reactions RTTNews · Oct 15, 2026
- Eton Licenses LIBERVANT For U.S. Seizure Rescue Market RTTNews · Oct 14, 2026
- Aquestive Therapeutics Resubmits NDA For Anaphylm Sublingual Film RTTNews · Sep 17, 2026
The company
Aquestive is a biopharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science. The worldwide leader in delivering trusted, quality medications on oral film, Aquestive operates as both a developer of its own proprietary products, with its headquarters in New Jersey and U.S.-based manufacturing facilities in Indiana. The Company is the exclusive manufacturer of four commercialized products marketed by its licensees across six continents using proprietary, best-in-class technologies like PharmFilm. Aquestive's AdrenaVerse platform contains a library of more than 20 epinephrine prodrugs enabling the pursuit of various potential allergy and dermatological indications. The Company is advancing Anaphylm (dibutepinephrine) sublingual film for the treatment of severe allergic reactions, including anaphylaxis, and AQST-108 (epinephrine) topical gel for various potential dermatological conditions.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GM
- Region
- North America
- Website
- aquestive.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.